Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.
Bharat Biotech to start human trials for first indigenous Covid-19 vaccine from July
A release from the company said the vaccine was developed in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
Human clinical trials of Bharat Biotech’s vaccine for coronavirus disease (Covid-19) will start from July, the Hyderabad-based biotechnology giant has said.

Bharat Biotech had claimed on Monday to have successfully developed India’s first Covid-19 vaccine, Covaxin, and said it has the permission from the Drug Controller General of India (DCGI) to start human clinical trials.
A release from the company said the vaccine was developed in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
“The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad,” it said.
It said the drug controller under the Union health ministry granted permission to initiate Phase I and II of human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response.
Human clinical trials are scheduled to start across India in July 2020.
Dr Krishna Ella, Bharat Biotech’s chairperson and managing director, said while announcing the vaccine development milestone that the company was proud to announce Covaxin.
“The collaboration with ICMR and NIV was instrumental in the development of this vaccine. The proactive support and guidance from the Central Drugs Standard Control Organisation (CDSCO) has enabled approvals to this project. Our research and development and manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform,” Ella said.
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses, Ella said.
Suchitra Ella, the company’s joint managing director, said Bharat Biotech’s ongoing research and expertise in forecasting epidemics had enabled it to successfully manufacture a vaccine for the H1N1 pandemic.
“We are committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future pandemics,” she said.

E-Paper
